Literaturverzeichnis Prof. Dr. med. R. Kimmig Originalarbeiten ...

Literaturverzeichnis
Prof. Dr. med. R. Kimmig
Originalarbeiten, Übersichten und
Buchbeiträge
1. Mikat B, Gellhaus A, Wagner N, Birdir C, Kimmig R, Köninger A.
Early detection of maternal risk for preeclampsia.
ISRN Obstet Gynecol. 2012;2012:172808. 2012 Jul 17.
2. Kuhlmann JD, Schwarzenbach H, Wimberger P, Poetsch M, Kimmig R,
Kasimir-Bauer S.
LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients
is predictive for tumor cell spread and overall survival.
BMC Cancer. 2012 Jul 31;12(1):325.
3. Buchbender C, Kuemmel S, Hoffmann O, Stahl AR, Kimmig R, Otterbach F,
Ladd S, Koeninger A, Forsting M, Bockisch A, Antoch G, Heusner TA.
FDG-PET/CT for the early prediction of histopathological complete response
to neoadjuvant chemotherapy in breast cancer patients: initial results.
Acta Radiol. 2012 Jul 1;53(6):628-36. 2012 Jul 3.
4. Garcia-Etienne CA, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A,
Kiechle M, Lorenz-Salehi F, Kimmig R, Emons G, Danaei M, Heyl V,
Heindrichs U, Rageth CJ, Janni W, Marotti L, Turco MR, Ponti A; eusoma DB
Working Group.
Mastectomy trends for early-stage breast cancer: A report from the EUSOMA
multi-institutional European database.
Eur J Cancer. 2012 Apr 4.
5. Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, Kimmig R, Forsting M,
Antoch G, Heusner TA.
Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of
axillary lymph node metastases in breast cancer patients.
Acta Radiol. 2012 Jun 1;53(5):518-23. 2012 Apr 30.
6. Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H,
Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G,
Dubois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger
W, Kuemmel S.
A randomized phase III adjuvant study in high-risk cervical cancer:
simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic
paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a
NOGGO-AGO Intergroup Study.
Ann Oncol. 2012 Feb 21.

7. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T.
Expression of stem cell and epithelial-mesenchymal transition markers in
primary breast cancer patients with circulating tumor cells.
Breast Cancer Res. 2012 Jan 20;14(1):R15.
8. Soliman AA, Heubner M, Kimmig R, Wimberger P.
Morbidity of inguinofemoral lymphadenectomy in vulval cancer.
ScientificWorldJournal. 2012;2012:341253.
9. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E,
Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A,
Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C,
Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W,
Parmar MK, Oza AM; ICON7 Investigators.
A phase 3 trial of bevacizumab in ovarian cancer.
N Engl J Med. 2011 Dec 29;365(26):2484-96. Erratum in: N Engl J Med. 2012
Jan 19;366(3):284.
10. van der Zee AG, Colombo N, Gitsch G, Reed N, Amant F, Cibula D, Kesic VI,
Kimmig R, Lopes AD, Markowska J, Marth C, Radolakis A, Salvesen H,
Vaitkiene D, Verheijen RH, Zola P.
ESGO statement on the role of CA-125 measurement in follow-up of epithelial
ovarian cancer.
Int J Gynecol Cancer. 2012 Jan;22(1):175.
11. Verheijen RH, Cibula D, Zola P, Reed N; council of the European Society of
Gynaecologic Oncology, Kimmig R.
Cancer antigen 125: lost to follow-up?: a European society of gynaecological
oncology consensus statement.
Int J Gynecol Cancer. 2012 Jan;22(1):170-4.
12. Mikat B, Zeller A, Scherag A, Drommelschmidt K, Kimmig R, Schmidt M.
βhCG and PAPP-A in First Trimester: Predictive Factors for Preeclampsia?
Hypertens Pregnancy. 2011 Dec 9.
13. Sismondi P, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, Planellas J,
Moggio G, Mol-Arts M, Kenemans P.
Effects of tibolone on climacteric symptoms and quality of life in breast cancer
patients-Data from LIBERATE trial.
Maturitas. 2011 Dec;70(4):365-72.
14. Hoffmann O, Aktas B, Goldnau C, Heubner M, Oberhoff C, Kimmig R,
Kasimir-Bauer S.
Effect of ibandronate on disseminated tumor cells in the bone marrow of
patients with primary breast cancer: a pilot study.
Anticancer Res. 2011 Oct;31(10):3623-8.
15. Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F,
Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V,
Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.
Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With
or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer:
Results of the NOGGO-AGO Intergroup Study.

J Clin Oncol. 2011 Aug 22.
16. Yang W, Wagener J, Wolf N, Schmidt M, Kimmig R, Winterhager E, Gellhaus
A.
Impact of CCN3 (NOV) glycosylation on migration/invasion properties and cell
growth of the choriocarcinoma cell line Jeg3.
Hum Reprod. 2011 Oct;26(10):2850-60.
17. Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P.
Molecular profiling and prognostic relevance of circulating tumor cells in the
blood of ovarian cancer patients at primary diagnosis and after platinumbased
chemotherapy.
Int J Gynecol Cancer. 2011 Jul;21(5):822-30.
18. Heinrich B; Kimmig R., Komitee für Praktische Onkologie.
[Asbestos-induced diseases: an on-going problem].
MMW Fortschr Med. 2011 Jun 2;153(22):34.
19. Hoffmann O, Heubner M, Anlasik T, Winterhalter M, Dahlmann B, Kasimir-
Bauer S, Kimmig R, Wohlschlaeger J, Sixt SU.
Circulating 20S Proteasome in Patients with Non-metastasized Breast
Cancer.
Anticancer Res. 2011 Jun;31(6):2197-201.
20. Sauerwein W, Hoffmann O., Schütte, M., Aktas B., Abu Jawad J., Stuschke,
M. Kimmig R.
Intraoperative Irradiation of the Tumor bed as a Boost in the Burst-sustaining
Primary treatment of Breast cancer - Initial results and issues that arises
Strahlentherapie und Onkologie 2011;187 (Suppl.1):99-100.
21. Cibula D, Verheijen R, Lopes A, Amant F, Beller U, Colombo N, Gitsch G,
Kesic V, Kimmig R, Markowska J, Marth C, Reed N, Rodolakis A, Salvesen
H, Vaitkiene D, van der Zee AG, Zola P.
Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology:
European Society of Gynecological Oncology (ESGO) Statement.
Int J Gynecol Cancer. 2011 Jun 28.
22. Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P,
Worm KH, Kimmig R, Kasimir-Bauer S.
Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the
presence of disseminated tumor cells in the bone marrow of ovarian cancer
patients before and after chemotherapy.
Genes Chromosomes Cancer. 2011 Aug;50(8):598-605. doi:
10.1002/gcc.20882
23. Erim Y, Beckmann M, Hoffmann O, Wimberger, P., Kimmig, R.
Predictors of Psychological Stress in Breast Cancer Patients - What Should
Physicians and Nursing Staff Pay Attention to in an Oncological Setting?
Geburtshilfe und Frauenheilkunde 2011 Apr.2011; 71 (4), 285-291.
24. Kimmig in: Janni W., Maass, N.
Robotic Surgery in der Gynäkologie – Chirurgie der Zukunft oder teurer PR-
Gag?
Der Gynäkologe 5/2011; 401-404

25. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L,
Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-
Lauraine E; on behalf of Gynecologic Cancer Intergroup.
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal
doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic
Cancer Intergroup (GCIG) CALYPSO sub-study.
Ann Oncol. 2011 Mar 14.
26. Heubner M, Errico D, Kasimir-Bauer S, Herlyn D, Kimmig R, Wimberger P.
EpCAM-autoantibody levels in the course of disease of ovarian cancer
patients.
Med Oncol. 2011 Jun;28(2):626-30.Epub 2010 Apr.
27. Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach
H.
Impact of platinum-based chemotherapy on circulating nucleic acid levels,
protease activities in blood and disseminated tumor cells in bone marrow of
ovarian cancer patients.
Int J Cancer. 2011 Jun 1; 128(11):2572-80.doi:10.1002/ijc.25602.Epub 2010
Oct.
28. Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters
J, Wohlschlaeger J, Sixt SU.
The prognostic impact of circulating proteasome concentrations in patients
with epithelial ovarian cancer.
Gynecol Oncol. 2011 Feb;120(2):233-8.
29. Goldnau C., Köninger A, Kimmig R.
[The female external genitalia: Pathologic findings and first steps in
treatment.]
Urologe A. 2010 Dec;49(12):1496-502.
30. Mensah J, Kimmig R, Schmidt M.
Ovarian Hyperstimulation Syndrome in an Aneuploid Pregnancy
Geburtshilfe und Frauenheilkunde 2010 Oct.; 70 (10): 828-831.
31. Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA,
Antoch G, Bockisch A, Kimmig R, Schmid KW, Stahl AR.
The XbaI G>T polymorphism of the glucose transporter 1 gene modulates
18F-FDG uptake and tumor aggressiveness in breast cancer.
J Nucl Med. 2010 Aug;51(8):1191-7.
32. Hauth E, Umutlu L, Kümmel S, Kimmig R. et al
Follow-up of Probably Benign Lesions (BI-RADS 3 category) in Breast MR
Imaging
Breast Journal 2010 May-Jun;16(3) 297-304
33. Landt S, Sina F, Kimmig R, Schmidt M.
[H1N1--pregnancy as risk factor]
Z Geburtshilfe Neonatol. 2010 Apr;214(2):48-51. 2010 Apr 21. German.
34. Barbara Mikat, Rainer Kimmig, Markus Schmidt
Diagnostik und Therapie der Präeklampsie – State of the Art

Gynäkologie 2010
35. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F,
Kimmig R, Siffert W.
The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial
ovarian neoplasms.
Oncol Res. 2010;18(7):343-7.
36. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A,
Harter P, Pfisterer J, du Bois A.
Influence of Residual Tumor on Outcome in Ovarian Cancer Patients with
FIGO Stage IV Disease: An Exploratory Analysis of the AGO-OVAR
(Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study
Group).
Ann Surg Oncol. 2010 Jun;17(6):1642-8. 2010 Feb 18.
37. Otterbach F, Callies R, Adamzik M, Kimmig R., Siffert W, Schmid KW,
Bankfalvi A
Aquaporin 1 (AQP1) expression is a novel characteristic feature of a
particularly aggressive subgroup of basal-like breast carcinomas
BREAST CANCER RESEARCH AND TREATMENT 2010;120 (1):67-76
38. Tan S, Scherag A, Janssen OE, Hahn S, Lahner H, Dietz T, Scherag S,
Grallert H, Vogel CI, Kimmig R, Illig T, Mann K, Hebebrand J, Hinney A.
Large effects on body mass index and insulin resistance of fat mass and
obesity associated gene (FTO) variants in patients with polycystic ovary
syndrome (PCOS).
BMC Med Genet. 2010 Jan 21;11(1):12.
39. Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig
R, Nuckel H.
Association of the AA genotype of the BCL2 (-938C>A) promoter
polymorphism with better survival in ovarian cancer.
Int J Biol Markers. 2009 Oct-Dec;24(4):223-9.
40. Hoffmann O, Solomayer E, Kuemmel S, Hahn M, Kasimir-Bauer S.), Kimmig
R, Wallwiener D, Fehm T.
Does Primary Systemic Therapy Erradicate Disseminated and Circulating
Tumor Cells?
Cancer Research 2009;69 Suppl. 24: 647 S-647 S
41. Wimberger P. Schröder W. Kimmig R.
Epitheliales Ovarialkarzinom. Neue molekularbiologische Ansätze
Management des Ovarialkarzinoms Hrsg. Kreienberg et. Al
Springer Verlag 2009; S. 218-230; ISBN 978-3-540-41987-7.
42. P. Wimberger, P. Sevelda, R. Kimmig
Schwangerschaftsbedingte Trophoblasttumoren
Die Onkologie 2. Auflage, Teil 2, 2009;1022 – 1037
43. Erim Y, Beckmann M, Gerlach G, Kümmel S, Oberhoff C, Senf W, Kimmig R.
[Screening for distress in women with breast cancer diagnosed for the first
time: employment of HADS-D and PO-Bado]
Z Psychosom Med Psychother. 2009;55(3):248-62. German.

44. Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R,
Kasimir-Bauer S.
Comparative evaluation of cell-free tumor DNA in blood and disseminated
tumor cells in bone marrow of patients with primary breast cancer.
Breast Cancer Res. 2009 Sep 21;11(5):R71.
45. P. Wimberger, R. Kimmig
Gynäkologische Malignome - Das Sentinelkonzept ist nicht immer geeignet
Info Onkologie 02/2009, S. 37 - 41
46. Mönckedieck V, Sannecke C, Husen B, Kumbartski M, Kimmig R, Tötsch M,
Winterhager E, Grümmer R.
Progestins inhibit expression of MMPs and of angiogenic factors in human
ectopic endometrial lesions in a mouse model.
Mol Hum Reprod. 2009 Oct;15(10):633-43. 2009 Aug 11.
47. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D,
Kimmig R, Kasimir-Bauer S.
Detection and characterization of circulating tumor cells in blood of primary
breast cancer patients by reverse-transcriptase polymerase chain reaction
and comparison to status of bone marrow disseminated cells.
Breast Cancer Res. 2009 Aug 10;11(4):R59.
48. Heubner M, Wimberger P, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert
W.
The AA genotype of a L1C G842A polymorphism is associated with an
increased risk for ovarian cancer.
Anticancer Res. 2009 Aug;29(8):3449-52.
49. Untch M., Beckmann MW.,Emons G., Thomssen Ch, Kimmig R
Tibolon erhöht das Rezidivrisiko bei Mammakarzinompatientinnen – neueste
Daten aus der LIBERATE-Studie.
Frauenheilkunde up2date 2009;3 (6) 168-172
50. Untch, M., Beckmann, MW, Emons, G., Thomssen C., Kimmig R.
The LIBERATE Study: Hormone Replacement Therapy with Tibolone
Increases the Risk of Recurrence and Metastases in Breast Cancer Patients
Geburtshilfe Frauenheilkd. 2009;69(3): 199-201
51. Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück
HJ, Kimmig R, Pfisterer J
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial
ovarian cancer and relapse within 12 months following 1st-line
platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial
by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer
Study Group (AGO-OVAR).
Gynecol Oncol. 2009 Aug;114(2):199-205.
52. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S.
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed
in circulating tumor cells of metastatic breast cancer patients.
Breast Cancer Res. 2009 Jul 9;11(4):R46

53. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, Kasimir-Bauer S.
Molecular profiling and predictive value of circulating tumor cells in patients
with metastatic breast cancer: an option for monitoring response to breast
cancer related therapies.
Breast Cancer Res Treat. 2009 Jun;115(3):581-90.
54. Wimberger P, Kimmig R.
Significance of laparoscopy in gynaecological oncology: limitations for
adnexal tumours
Gynakol Geburtshilfliche Rundsch. 2009;49(3):133-7.
55. Fink D, Lang U, Kimmig R.
Use of laparoscopy in gynecological oncology
Gynakol Geburtshilfliche Rundsch. 2009;49(3):109-10.
56. Schmidt M, Hoffmann B, Kimmig R, Kasimir-Bauer S.
mRNA of Placental Origin in Maternal Serum of Women with Normal and
Preeclamptic Pregnancies.
Fetal Diagn Ther. 2009 Jun 11;25(2):269-276
57. Wimberger P, Heubner M, Lindhofer H, Jäger M, Kimmig R, Kasimir-Bauer S.
Influence of catumaxomab on tumor cells in bone marrow and blood in
ovarian cancer.
Anticancer Res. 2009 May;29(5):1787-91.
58. Emons G, Kimmig R.
Interdisciplinary S2k guidelines on the diagnosis and treatment of endometrial
carcinoma.
J Cancer Res Clin Oncol. 2009 Oct;135(10):1387-91.
59. Schmidt M, Dogan C, Birdir C, Kuhn U, Gellhaus A, Kimmig R, Kasimir-Bauer
S.
Placental growth factor: a predictive marker for preeclampsia?
Gynakol Geburtshilfliche Rundsch. 2009;49(2):94-9.
60. Imthurn B, Kimmig R, Lang U, Fink D.
New developments in reproductive medicine
Gynakol Geburtshilfliche Rundsch. 2009;49(2):53-4.
61. Hauth EA, Umutlu L, Libera H, Kimmig R, Forsting M.
Magnetic resonance imaging of the pelvis in patients with polycystic ovary
syndrome
Rofo. 2009 Jun;181(6):543-8.
62. Schmidt M, Callies R, Kuhn U, Willruth A, Kimmig R.
External cephalic version in cases of breech presentation: renaissance of a
well-known procedure?
Gynakol Geburtshilfliche Rundsch. 2009;49(1):29-34.
63. Lang U, Fink D, Kimmig R.
Intrauterine programming of specific organ systems]
Gynakol Geburtshilfliche Rundsch. 2009;49(1):1.

64. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi
P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os
S, Beckmann MW; LIBERATE Study Group.
Safety and efficacy of tibolone in breast-cancer patients with vasomotor
symptoms: a double-blind, randomised, non-inferiority trial.
Lancet Oncol. 2009 Feb;10(2):135-46.
65. Heubner M, Riemann K, Otterbach F, Kimmig R, Kasimir-Bauer S, Siffert W,
Wimberger P.
The haplotype of two FSHR polymorphisms in ovarian cancer- A potential role
of ethnology in risk modification.
Gynecol Oncol. 2009 Mar; 112 (3): 486-9.
66. B. Aktas, M. Tewes, S. Hauch, R. Kimmig, S. Kasimir-Bauer
Zirkulierende Tumorzellen beim metastasierten Mammakarzinom
Med Review 02/2009, S 3 - 4
67. Wimberger P, Kimmig R.
The role of radical lymphadenectomy: Experiences from the AGO Ovarian
Cancer Study Group.
Urologe A. 2009 Jan; 48 (1):26-31.2008 Dec 7
68. M.W. Beckmann, G. Emons, R. Kimmig, P. Mallmann
AGO: Aktuelles aus S2 k-Leitlinien zur Diagnostik und Therapie des
Endometriumkarzinoms und des Zervixkarzinoms
Forum 2 2008 Deutsche Krebsgesellschaft e.V.
69. Otterbach F, Callies R, Kimmig R, Schmid KW, Bánkfalvi A.
Aquaporin 1 expression in invasive breast carcinomas]
Pathologe. 2008 Nov;29 Suppl 2:357-62.
70. Lang U, Fink D, Kimmig R.
Fetal programming]
Gynakol Geburtshilfliche Rundsch. 2008;48(4):205-6.
71. Hilpert F, Harter P, Wimberger P, Kimmig R, Pfisterer J, du Bois A
Treatment of elderly patients with advanced ovarian cancer in the context of
controlled clinical trials - A joint analysis of 3 AGO-Ovar subprojects
Geburtshilfe Frauenheilkd. 2008;68 Suppl. : S13-S13
72. Hauth EA, Umutlu L, Quinsten A, Kummel S, Kimmig R, Forsting M
MR-guided vacuum assisted breast biopsy with the ATEC (R) breast biopsy
and excision system
Geburtshilfe Frauenheilkd. 2008;68(9): 901-906
73. Distler W, Beckmann MW, Kimmig R, Runnebaum I, Eiermarnn W
ATAC-Study: 100 months lasting analyze shows that after therapy ending
considered effectiveness of Anastrozol versus Tamoxifen Carry-over-Effect
benefits in adjustment of fractured rat in Arimidex, Tamoxifen, Alone or in
Combination (ATAC)-Study
Geburtshilfe Frauenheilkd. 2008;68 Suppl. : S30-S30

74. Birdir C, Callies R, Schmidt M, Stein A, Kimmig R
Tuberculosis pericarditis constrictive in the pregnancy - A Case report
Geburtshilfe Frauenheilkd. 2008;68(3): 310-310
75. Wimberger, P, Welt A, Kimmig R.
Infertilität: Prophylaxe und Behandlung
Supportive Therapie in der Onkologie 2008 11/2008 463-475.
76. Nierwetberg D, Schmidt M, Kimmig R.
[Hormone replacement therapy and cancer risk]
MMW Fortschr Med. 2008 Oct 23;150(43):27-8.
77. Köninger A, Kümmel S, Kimmig R.
[Hormone replacement therapy in patients after breast cancer]
MMW Fortschr Med. 2008 Oct 23;150(43):32-4.
78. Allhorn S, Böing C, Koch AA, Kimmig R, Gashaw
TLR3 and TLR4 expression in healthy and diseased human endometrium.
Reprod Biol Endocrinol. 2008 Sep 7;6(1):40.
79. Hauth EA, Jaeger HJ, Lubnau J, Maderwald S, Otterbach F, Kimmig R,
Forsting MR-guided vacuum-assisted breast biopsy with a handheld biopsy
system: clinical experience and results in postinterventional MR
mammography after 24 h.
Eur Radiol. 2008;18(1): 168-76
80. Tan S, Hahn S, Benson S, Janssen OE, Dietz T, Kimmig R, Hesse-Hussain
J, Mann K, Schedlowski M, Arck PC, Elsenbruch S.
Psychological implications of infertility in women with polycystic ovary
syndrome.
Hum Reprod. 2008 Sep.;23(9):2064-71.
81. Fink D, Lang U, Kimmig R.
[Fundamental advances in the adjuvant systemic therapy of breast cancer]
Gynakol Geburtshilfliche Rundsch. 2008;48(3):111-2.
82. Schmidt M, Hoffmann B, Beelen D, Gellhaus A, Winterhager E, Kimmig R,
Kasimir-Bauer S.
Detection of circulating trophoblast particles in peripheral maternal blood in
preeclampsia complicated pregnancies.
Hypertens Pregnancy. 2008;27(2):131-42.
83. Kummel S, Heidecke H, Brock B, Denkert C, Hecktor J, Koninger A, Becker I,
Sehouli J, Thomas A, Blohmer JU, Lichtenegger W, Kimmig R.
[Imatinib--a possible therapeutic option for cervical carcinoma: results of a
preclinical phase I study]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):94-100.
84. Hauth EA, Hoffmann O, Zadow-Eulerich T, Kimmig R, Forsting M.
[Magnetic resonance tomography in the diagnostics of breast implants: a
survey]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):76-83.

85. Blohmer JU, Kimmig R, Kummel S, Costa SD, Kramer S, Rezai M.
[Intraoperative radiotherapy of breast cancer]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):63-7.
86. Kramer S, Darsow M, Kummel S, Kimmig R, Rezai M.
Breast-conserving treatment of breast cancer--oncological and reconstructive
aspects.
Gynakol Geburtshilfliche Rundsch. 2008;48(2):56-62.
87. Kimmig R, Fink D, Lang U.
[Physical integrity versus oncological safety: synthesis of important aspects in
the treatment of breast cancer]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):55.
88. Gashaw I, Stiller S, Böing C, Kimmig R, Winterhager E.
Pre-menstrual regulation of the pro-angiogenic factor CYR61 in human
endometrium.
Endocrinology. 2008 May;149(5):2261-9.
89. Hauth EA, Jaeger H, Maderwald S, Mühler A, Kimmig R, Forsting M.
[Quantitative parametric analysis of contrast-enhanced lesions in dynamic MR
mammography.]
Radiologe. 2008 Jun;48(6):593-600.
90. Schmidt M, Dogan C, Birdir C, Callies R, Kuhn U, Gellhaus A, Janetzko A,
Kimmig R, Kasimir-Bauer S.
Altered angiogenesis in preeclampsia: evaluation of a new test system for
measuring placental growth factor.
Clin Chem Lab Med. 2007;45(11):1504-10.
91. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, Schmidt M,
Elsenbruch S, Kimmig R, Mann K, Janssen OE.
Metformin improves polycystic ovary syndrome symptoms irrespective of pretreatment
insulin resistance.
Eur J Endocrinol. 2007 Nov;157(5):669-76.
92. Fechner S, Husen B, Thole H, Schmidt M, Gashaw I, Kimmig R, Winterhager
E, Grummer R.
Expression and regulation of estrogen-converting enzymes in ectopic human
endometrial tissue.
Fertil Steril. 2007 Oct;88(4 Suppl):1029-38. 2007 Feb 20.
93. Hauth EA, Kimmig R, Forsting M.
[Diagnosis of vulval and vaginal neoplasms with magnetic resonance imaging]
Gynakol Geburtshilfliche Rundsch. 2007;47(4):226-35.
94. Schmidt M, Kimmig R.
[Pathophysiology of preeclampsia]
Gynakol Geburtshilfliche Rundsch. 2007;47(4):199-204.
95. Schmidt M, Fink D, Lang U, Kimmig R.
[Hypertensive diseases during pregnancy: an interdisciplinary challenge]
Gynakol Geburtshilfliche Rundsch. 2007;47(4):197-8.

96. Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, Siffert
W, Kimmig R.
The AA Genotype of the Regulatory BCL2 Promoter Polymorphism ( 938C>A)
Is Associated with a Favorable Outcome in Lymph Node Negative Invasive
Breast Cancer Patients.
Clin Cancer Res. 2007 Oct 1;13(19):5790-7.
97. Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir-Bauer S.
Influence of platinum-based chemotherapy on disseminated tumor cells in
blood and bone marrow of patients with ovarian cancer.
Gynecol Oncol. 2007 Aug 30;
98. Mobus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R,
Ostermann H, Hinke A, Ledermann JA; AGO-Ovar/AIO; EBMT.
Phase III trial of high-dose sequential chemotherapy with peripheral blood
stem cell support compared with standard dose chemotherapy for first-line
treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO
and EBMT.
J Clin Oncol. 2007 Sep 20;25(27):4187-93. 2007 Aug 13.
99. Mobus V, Wandt H, Frickhofen N, Bengala C, Champion K,
Kimmig R, Ostermann H, Hinke A, Ledermann JA.
High-Dose Sequential Chemotherapy With Peripheral Blood
Stem Cell Support Compared With Standard Dose
Chemotherapy for First-Line Treatment of Advanced
Ovarian Cancer: Results of a Phase III Intergroup Trial of
the AGO-Ovar/AIO and EBMT.
J Clin Oncol. 2007 Aug 13;
100. Schmidt M, Kimmig R, Kasimir-Bauer S, et al.
Determination of serum PLGF by ELISA in normal and preeclamptic
pregnancies.
CLINICAL CHEMISTRY 53 (6): A209-A209 D155 Suppl. S JUN 2007
101. Böing C, Kimmig R.
[Stage-adapted treatment of cervical carcinoma]
MMW Fortschr Med. 2007 Mar 22;149(12):32-4.
102. Kimmig R.
[Vaccination against human papilloma virus. Has cervical cancer been
beaten?]
MMW Fortschr Med. 2007 Mar 22;149(12):28-9
103. Hahn S, Backhaus M, Broecker-Preuss M, Tan S, Dietz T, Kimmig R,
Schmidt M, Mann K, Janssen OE.
Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome
women with obesity and impaired glucose metabolism.
Eur J Endocrinol. 2007 Aug;157(2):201-7.
104. Hauth EA, Jaeger HJ, Maderwald S, Muehler A, Kimmig R, Forsting M.
Quantitative 2- and 3-dimensional analysis of pharmacokinetic model-derived
variables for breast lesions in dynamic, contrast-enhanced MR
mammography.

Eur J Radiol. 2007 Jul 18;
105. Boing C, Kimmig R.
[Surgical management of endometriosis--an overview]
Gynakol Geburtshilfliche Rundsch. 2007;47(3):124-31.
106. Fink D, Lang U, Kimmig R.
[Endometriosis—a frequently underestimated disease]
Gynakol Geburtshilfliche Rundsch. 2007;47(3):111-2.
107. Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt
B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E,
Jager M, Strohlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R.
Effective relief of malignant ascites in patients with advanced ovarian cancer
by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Clin Cancer Res. 2007 Jul 1;13(13):3899-905.
108. Lang U, Fink D, Kimmig R.
[Multiple pregnancies--Part 2]
Gynakol Geburtshilfliche Rundsch. 2007;47(2):55-6.
109. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A;
Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study
Group.
Prognostic factors for complete debulking in advanced ovarian cancer and its
impact on survival. An exploratory analysis of a prospectively randomized
phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie
Ovarian Cancer Study Group (AGO-OVAR).
Gynecol Oncol. 2007 Jul;106(1):69-74. 2007 Mar 29.
110. Matuszczyk A, Petersenn S, Lahner H, Haude M, Veit P, Becker JU, Kimmig
R, Bockisch A, Mann K.
Leydig cell tumor as a cause of hirsutism in a postmenopausal woman.]
Med Klin (Munich). 2007 Mar 15;102(3):259-62.
111. Kummel S, Rezai M, Kimmig R, Schmid P.
Dose-dense chemotherapy for primary breast cancer.
Curr Opin Obstet Gynecol. 2007 Feb;19(1):75-81.
112. Lang U, Fink D, Kimmig R.
[Multiple pregnancies]
Gynakol Geburtshilfliche Rundsch. 2007;47(1):1-2
113. Hahn S, Kuehnel W, Tan S, Kramer K, Schmidt M, Roesler S, Kimmig R,
Mann K, Janssen OE.
Diagnostic value of calculated testosterone indices in the assessment of
polycystic ovary syndrome.
Clin Chem Lab Med. 2007;45(2):202-7.
114. Hahn S, Tan S, Sack S, Kimmig R, Quadbeck B, Mann K, Janssen OE.
Prevalence of the metabolic syndrome in german women with polycystic
ovary syndrome.
Exp Clin Endocrinol Diabetes. 2007 Feb;115(2):130-5.

115. Hauth EA, Khan K, Wolfgarten B, Betzler A, Kimmig R, Forsting M.
[Evaluation of the results after using of the BI-RADS categories in 1,777
clinical mammograms.]
Radiologe. 2007 Jan 31;
116. Otterbach F, Callies R, Frey UH, Schmitz KJ, Wreczycki C, Kimmig R, Siffert
W, Schmid KW.
The T393C polymorphism in the gene GNAS1 of G protein is associated with
survival of patients with invasive breast carcinoma.
Breast Cancer Res Treat. 2006 Dec 21;
117. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, Kimmig
R, Mann K, Janssen OE.
Low serum 25-hydroxyvitamin D concentrations are associated with insulin
resistance and obesity in women with polycystic ovary syndrome.
Exp Clin Endocrinol Diabetes. 2006 Nov;114(10):577-83.
118. Schmidt M, Fink D, Lang U, Kimmig R.
[Hormone replacement therapy: curse or blessing?]
Gynakol Geburtshilfliche Rundsch. 2006;46(4):165
119. Schmidt M, Kimmig R.
[The benefits and risks of hormonal replacement therapy--an update]
Gynakol Geburtshilfliche Rundsch. 2006;46(4):166-73.
120. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U,
Stahle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley
J, Jackisch C, Luck HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-
OVAR; NCIC CTG; EORTC GCG.
Gemcitabine plus carboplatin compared with carboplatin in patients with
platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-
OVAR, the NCIC CTG, and the EORTC GCG.
J Clin Oncol. 2006 Oct 10;24(29):4699-707. 2006.
121. Pfisterer J., du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U,
Belau A, Jackisch C., Kimmig R., Wollschlaeger K, Heilmann V, Hilpert F.
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian
cancer. A phase I trial of the AGO-OVAR.
Ann Oncol. 2006 Oct;17(10):1568-1577.
122. Wimberger P., Kasimir-Bauer S, Weck B., Kimmig R.
Antikörpertherapien beim Ovarialkarzinom
Frauenarzt (2006); 10; 920 – 923
123. Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois
H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stahle A, Jackisch
C, Hardy-Bessard AC, Mobus V, Quaas J, Richter B, Schroder W, Geay JF,
Luck HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR;
GINECO.
Randomized phase III trial of topotecan following carboplatin and paclitaxel in
first-line treatment of advanced ovarian cancer: a gynecologic cancer
intergroup trial of the AGO-OVAR and GINECO.
J Natl Cancer Inst (2006); 2;98(15):1036-45

124. Böing C, Kimmig R.
Fertility-preserving treatment in young women with endometrial cancer.
Gynäkol Geburtsh. Rundsch (2006);46(1-2):25-33
Schmitz KJ, Callies R, Wohlschlaeger J, Kimmig R, Otterbach F, Bohr J, Lee
HS, Takeda A, Schmid KW, Baba HA.
Overexpression of cyclo-oxygenase-2 is an independent predictor of
unfavourable outcome in node-negative breast cancer, but is not associated
with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2,
p38) activation or with Her-2/neu signalling pathways.
J Clin Pathol (2006);59(7):685-91
125. Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K, Schedlowski M,
van Halteren WB, Kimmig R, Janssen OE.
Metformin treatment of polycystic ovary syndrome improves health-related
quality-of-life, emotional distress and sexuality.
Hum Reprod (2006);21(7):1925-34
126. Kimmig R, Fink D, Lang U.
Organ preservation, multimodal radical tumor therapy and reduction of
therapy-related morbidity--development of diagnostics and therapy of
endometrial carcinoma.
Gynäkol Geburtsh. Rundsch (2006);46(1-2):1-2
127. Hauth EA, Jaeger H, Maderwald S, Stockamp C, Muhler A, Kimmig R,
Forsting M.
Evaluation of quantitative parametic analysis for characterization of breast
lesions in constrast-enhanced MR mammography.
Eur Radiol (2006);29
128. Fink D, Perucchini D, Lang U, Kimmig R.
Urinary incontinence and descensus genitalis--the silent sickness.
Gynäkol Geburts. Rundsch (2006);46(3):77-8
129. Hauth EA, Stockamp C, Maderwald S, Muhler A, Kimmig R, Jaeger H,
Barkhausen J, Forsting M.
Evaluation of the three-time-point method for diagnosis of breast lesions in
contrast-enhanced MR mammography.
Clin Imaging (2006);30(3):160-5
130. Gellhaus A, Schmidt M, Dunk C, Lye SJ, Kimmig R, Winterhager E.
Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV
(CCN3) in human placenta is associated with pre-eclampsia.
Mol Hum Reprod (2006);12(6):389-99
131. Elsenbruch S, Benson S, Hahn S, Tan S, Mann K, Pleger K, Kimmig R,
Janssen OE.
Determinants of emotional distress in women with polycystic ovary syndrome.
Hum Reprod (2006);21(4):1092-9
132. Hauth EA, Kimmig R, Forsting M.
Magnetic resonance imaging (MRI) of the pelvis in the diagnosis of cervical
carcinoma – review.
Zentralbl Gynäkol (2006);128(2):60-7

133. Hahn S, Bering van Halteren W, Roesler S, Schmidt M, Kimmig R, Tan S,
Mann K, Janssen OE.
The combination of increased ovarian volume and follicle number is
associated with more severe hyperandrogenism in German women with
polycystic ovary syndrome.
Exp Clin Endocrinol Diabetes (2006);114(4):175-81
134. Hauth EA, Reiter K., Kimmig R., Forsting M.
Die Magnetresonanztomographie (MRT)-gesteuerte Mamma-Vakuumbiopsie
mit dem Vacora®-System.
RöFo (2006); S1 178,VO 322.7
135. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner
S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R,
Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA.
MT110: a novel bispecific single-chain antibody construct with high efficacy in
eradicating established tumors.
Mol Immunol (2006);43(8):1129-43
136. Hauth E, Libera H, Kimmig R, Forsting M.
MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer
patients in tamoxifen therapy.
Röfo (2006);178(3):316-23
137. du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats JC,
Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S,
Schroeder W, Kimmig R, Pujade-Lauraine E; Arbeitsgemeinschaft
Gynaekologische Onkologie; Ovarian Cancer Study Group; Groupe
d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line
treatment of advanced ovarian cancer: a prospectively randomized
gynecologic cancer intergroup trial by the Arbeitsgemeinschaft
Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe
d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
J Clin Oncol (2006);1;24(7):1127-35
138. Schmalfeldt B, du Bois A, Burges A, Emons G, Fink D, Gropp M, Hasenburg
A, Jager W, Kimmig R, Kiechle M, Kommoss F, Kreienberg R, Kuhn W, Luck
HJ, Meier W, Munstedt K, Ortmann O, Pfisterer J, Richter B, Runnebaum I,
Schroder W, Sehouli J, Tanner B, Wagner U, Weis J.
Diagnosis and treatment of malignant ovarian tumors 2005: recommendations
of the Kommission Ovar of the AGO.
Zentralbl Gynäkol (2006);128(1):11-7
139. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Hoppenau B, du
Bois A; AGO-OVAR.
Impact of age on outcome in patients with advanced ovarian cancer treated
within a prospectively randomized phase III study of the Arbeitsgemeinschaft
Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Gynecol Oncol (2006);100(2):300-7

140. Hahn S, Haselhorst U, Quadbeck B, Tan S, Kimmig R, Mann K, Janssen OE.
Decreased soluble leptin receptor levels in women with polycystic ovary
syndrome.
Eur J Endocrinol (2006);154(2):287-94
141. Schmitz KJ, Grabellus F, Callies R, Wohlschlaeger J, Otterbach F, Kimmig R,
Levkau B, Schmid KW, Baba HA.
Relationship and prognostic significance of phospho-(serine 166)-murine
double minute 2 and Akt activation in node-negative breast cancer with regard
to p53 expression.
Virchows Arch (2006);448(1):16-23
142. du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch
C, Staehle A, Kimmig R, Elser G.
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic
tumors: a prospective phase I/II study of the Arbeitsgemeinschaft
Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
Ann Oncol (2006);17(1):93-6
143. Kimmig R, Wimberger P.
Antikörpertherapien beim Ovarialkarzinom.
ArzneimForsch DrugRes (2005);55 (11):22-3
144. Hauth EA, Reiter K, Hoffmann O, Otterbach F, Kimmig R, Forsting M.
MR-guided vacuum assisted breast biopsy.
Zentralbl Gynäkol (2005);127(6):400-6
145. Hauth EA, Wolfgarten B, Kimmig R, Forsting M.
MR imaging of the pelvis in characterization of adnexal masses
Zentralbl Gynäkol (2005);127(6):373-9
146. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, Kimmig R,
Benson S, Balamitsa E, Elsenbruch S.
Clinical and psychological correlates of quality-of-life in polycystic ovary
syndrome.
Eur J Endocrinol (2005);153(6):853-60
147. Seeger D, Truong ST, Kimmig R.
Spontaneous delivery following tension-free vaginal tape procedure.
Int Urogynecol J Pelvic Floor Dysfunct (2005) 28:1-3
148. Wimberger P, Kimmig R.
Surgical treatment of ovarian cancer
MMW Fortschr Med (2005); 27;147(43):31-3
149. Kimmig R.
Treatment of ovarian cancer-an update.
MMW Fortschr Med (2005);27;147(43):25-6
150. Hauth EA, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, Kimmig R,
Forsting M.
Evaluation of integrated whole-body PET/CT in the detection of recurrent
ovarian cancer.

Eur J Radiol (2005);56(2):263-8
151. Anthuber S, Hepp H, Fink D, Kimmig R, Lang U.
Contraception in young adolescents
Gynäkol Geburtsh. Rundsch (2005);45(4):223-4
152. Fink D, Kimmig R, Winter R.
Therapy of breast cancer-change from radical to quality-controlled
individualized treatment.
Gynäkol Geburtsh. Rundsch (2005);45(3):125-6
153. Heiss MM, Ströhlein MA, Jager M, Kimmig R, Burges A, Schoberth A, Jauch
KW, Schildberg FW, Lindhofer H.
Immunotherapy of malignant ascites with trifunctional antibodies.
Int J Cancer (2005); 10;117(3):435-43
154. Winter R, Kimmig R, Fink D.
Obstetric/Prenatal ultrasound: blessing or burden?
Gynäkol Geburtsh. Rundsch (2005);45(2):60-1
155. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva
A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P,
Kimmig R, Baeuerle PA.
Eradication of tumors from a human colon cancer cell line and from ovarian
cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3bispecific
antibody construct.
Cancer Res (2005); 1;65(7):2882-9
156. Hauth EA, Stattaus J, Kimmig R, Schmidt M, Forsting M.
Magnetic resonance imaging (MRI) of the pelvis in diagnosing endometriosis.
Zentralbl Gynäkol (2005);127(2):76-82
157. Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B,
Kimmig R, Schmid KW, Baba HA.
High expression of focal adhesion kinase (p125FAK) in node-negative breast
cancer is related to overexpression of HER-2/neu and activated Akt kinase
but does not predict outcome.
Breast Cancer Res (2005);7(2):R194-203
158. Grabellus F, Worm K, Willruth A, Schmitz KJ, Otterbach F, Baba HA, Kimmig
R, Metz KA.
ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-tofemale
transsexual.
Breast (2005);14(1):71-4
159. Anthuber S, Hepp H, Fink D, Kimmig R, Lang U.
Contraception in young adolescents
Gynäkol Geburtsh. Rundsch (2005);45(4):223-4
160. Kagan KO, Schmidt M, Kuhn U, Kimmig R.
Ventricular outflow obstruction, valve aplasia, bradyarrhythmia, pulmonary
hypoplasia and non-immune fetal hydrops because of a large rhabdomyoma
in a case of unknown tuberous sclerosis: a prenatal diagnosed cardiac
rhabdomyoma with multiple symptoms.
BJOG (2004);111(12):1478-80

161. Hauth EA, Antoch G, Ruehm SG, Boing C, Kimmig R, Forsting M.
Value of pelvic MRI in the preoperative diagnosis of endometriosis.
Rofo (2004);176(9):1265-70
162. Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, Hoffmann O,
Grabellus F, Kimmig R, Schmid KW, Baba HA.
Prognostic relevance of activated Akt kinase in node-negative breast cancer:
a clinicopathological study of 99 cases.
Mod Pathol (2004);17(1):15-21
163. Kasimir-Bauer S, Otterbach F, Oberhoff C, Schmid KW, Kimmig R, Seeber S.
Rare expression of target antigens for immunotherapy on disseminated tumor
cells in breast cancer patients without overt metastases.
Int J Mol Med (2003);12(6):969-75
164. Xiang W, Wimberger P, Dreier T, Diebold J, Mayr D, Baeuerle PA, Kimmig R.
Cytotoxic activity of novel human monoclonal antibody MT201 against primary
ovarian tumor cells.
J Cancer Res Clin Oncol (2003);129(6):341-8
165. Oduncu FS, Kimmig R, Hepp H, Emmerich B.
Cancer in pregnancy: maternal-fetal conflict.
J Cancer Res Clin Oncol (2003);129(3):133-46
166. Wimberger P, Xiang W, Mayr D, Diebold J, Dreier T, Baeuerle PA, Kimmig R.
Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in
primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Int J Cancer (2003);10;105(2):241-8
167. Wimberger P, Hillemanns P, Kapsner T, Hepp H, Kimmig R.
Evaluation of prognostic factors following flow-cytometric DNA analysis after
cytokeratin labelling: II. Cervical and endometrial cancer.
Anal Cell Pathol (2002);24(4-5):147-58
168. Wimberger P, Hillemanns P, Kapsner T, Hepp H, Kimmig R.
Evaluation of prognostic factors following flow-cytometric DNA analysis after
cytokeratin labelling: I. Breast cancer.
Anal Cell Pathol (2002);24(4-5):135-45
169. Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig
R, Rehbock J, Hölzel D.
Moderate progress for ovarian cancer in the last 20 years: prolongation of
survival, but no improvement in the cure rate.
Eur J Cancer (2002);38(18):2435-45
170. Otto T, Suhr J, Krege S, Goebell PJ, Wishahi M, Bier UW, Kimmig R,
Rübben H.
Surgical treatment of disseminated peritoneal metastases from urological
cancer: results from a prospective study.
BJU Int (2002);90(9):823-7

171. Hasbargen U, Summerer-Moustaki M, Hillemanns P, Scheidler J, Kimmig R,
Hepp H.
Uterine dehiscence in a nullipara, diagnosed by MRI, following use of unipolar
electrocautery during laparoscopic myomectomy: Case report.
Hum Reprod (2002);17(8):2180-2
172. Hasbargen U, Strauss A, Summerer-Moustaki M, Baretton G, Roth U,
Kimmig R, Hepp H.
Myomectomy as a pregnancy-preserving option in the carefully selected
patient.
Fetal Diagn Ther (2002);17(2):101-3
173. Kimmig R, Wimberger P, Hillemanns P, Kapsner T, Caspari C, Hepp H.
Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase
fraction in ovarian cancer determined by flow cytometry following detection of
cytokeratin-labeled tumor cells.
Gynecol Oncol (2002);84(1):21-31
174. Peiro G, Diebold J, Baretton GB, Kimmig R, Löhrs U.
Cellular apoptosis susceptibility gene expression in endometrial carcinoma:
correlation with Bcl-2, Bax, and caspase-3 expression and outcome.
Int J Gynecol Pathol (2001);20(4):359-67
175. du Bois A, Luck HJ, Pfisterer J, Schroeder W, Blohmer JU, Kimmig R,
Moebus V, Quaas J.
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer-
-a
dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie
(AGO) Ovarian Cancer Study Group.
Ann Oncol (2001);12(8):1115-20
176. Peiro G, Diebold J, Mayr D, Baretton GB, Kimmig R, Schmidt M, Lohrs U.
Prognostic relevance of hMLH1, hMSH2, and BAX protein expression in
endometrial carcinoma.
Mod Pathol (2001);14(8):777-83
177. Kimmig R, Wimberger P, Kapsner T, Hillemanns P.
Flow cytometric DNA analysis using cytokeratin labeling for identification of
tumor cells in carcinomas of the breast and the female genital tract.
Anal Cell Pathol (2001);22(3):165-78
178. Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H,
Slamon D, Pegram M.
Association of urokinase-type plasminogen activator and its inhibitor with
disease progression and prognosis in ovarian cancer.
Clin Cancer Res (2001);7(6):1743
179. Hillemanns P, Kimmig R, Hepp H.
Hormonale Substitution und extragenitale Neoplasien.
Gynäkologe (2000);33:416-22
180. Kimmig R, Hillemanns P, Hepp H.
Tibolon – eine Alternative zur Östrogensubstitution?

Gynäkologe (2000);33:408-15
181. Sevelda P, Kimmig R.
Schwangerschaftsbedingte Trophoblasterkrankungen. In: Lehrbuch der
Onkologie. Hrsg. W. Hiddemann, München; Huber, Wien; Bartram,
Heidelberg Springer Verlag (2000)
182. Kimmig R, Seehaus D, Hillemanns P, Hepp H.
Hormonelle Substitution und Mammakarzinom. In: Diagnostik und Therapie
des Mammakarzinoms. State of the art. Untch M. Konecny G, Sittek H,
Kessler M, Reiser M, Hepp H (eds.) 2 edn. (überarbeitete Auflage)
W Zuckschwerdt Verlag München Bern Wien New York (2000).
183. Hillemanns P, Dannecker C, Kimmig R, Hasbargen U.
Obstetric risks and vertical transmission of hepatitis C virus infection in
pregnancy.
Acta Obstet Gynecol Scand (2000);79(7):543-7
184. Hillemanns P, Kimmig R, Dannecker C, Noorzai T, Diebold J, Thaler CJ,
Hepp H.
LEEP versus cold knife conization for treatment of cervical intraepithelial
neoplasias
Zentralbl Gynäkol (2000);122(1):35-42
185. Kimmig R, Hillemanns P, Burges A, Hepp H.
Fertilitätserhaltung bei gynäkologischen Malignomen – Risikobezogene
Therapiestrategien. In: Neuerungen in der Onkologie. Utopie und
Wirklichkeit? Hrsg. Clemm Ch, Gutschow K.
W Zuckschwerdt Verlag ISBN 3-88603-669-3, (1999): S. 64-74
186. Kimmig R.
Durchflußzytometrische DNA-Analyse solider gynäkologischer Tumoren nach
Zytokeratinmarkierung zur Detektion der Tumorzellen.
Habitationsschrift Ludwig-Maximilians-Universität München 1999
187. Hillemanns P, Kimmig R, Huttemann U, Dannecker C, Thaler CJ.
Screening for cervical neoplasia by self-assessment for human papillomavirus
DNA.
Lancet (1999);4;354(9194):1970
188. Hillemanns P, Korell M, Schmitt-Sody M, Baumgartner R, Beyer W, Kimmig
R, Untch M, Hepp H.
Photodynamic therapy in women with cervical intraepithelial neoplasia using
topically applied 5-aminolevulinic acid.
Int J Cancer (1999);31;81(1):34-8
189. Kimmig R.
5. Recurrent cervical carcinoma – an invited comment.
Hungar J Gynecol Oncol (1998)
190. Kimmig R, Strowitzki T, Hepp H.
Moderately differentiated endometrial carcinoma cured by conservative
treatment. Letter to the Editor.
Int J Gynecol Cancer (1998);8:511-2

191. Kimmig R, Seehaus D, Hillemanns P, Hepp H.
Hormonelle Substitution und Mammakarzinom. In: Diagnostik und Therapie
des Mammakarzinoms. State of the art. Untch M, Konecny G, Sittek H,
Kessler M, Reiser M, Hepp H (eds).
W Zuckschwerdt Verlag München Bern Wien New York (1998): S. 77-82
192. Singer GA, Strowitzki T, Rettig I, Kimmig R.
Flow cytometric detection and binding studies of human endometrial stromal
cell epidermal growth factor receptor in monolayer culture: influence of
progesterone.
Mol Hum Reprod (1998);4(6):577-83
193. Loscar M, Schelling G, Haller M, Polasek J, Stoll C, Kreimeier U, Finsterer U,
Steitz HO, Baumeister R, Kimmig R, Grabein B, Briegel J.
Group A streptococcal toxic shock syndrome with severe necrotizing fasciitis
following hysterectomy--a case report.
Intensive Care Med (1998);24(2):190-3
194. Pfeiffer D, Kimmig R, Herrmann J, Ruge M, Fisseler-Eckhoff A, Scheidel P,
Jensen A, Schatz H, Pfeiffer A.
Epidermal-growth-factor receptor correlates negatively with cell density in
cervical squamous epithelium and is down-regulated in cancers of the human
uterus.
Int J Cancer (1998);20;79(1):49-55
195. Scheidler J, Heuck AF, Steinborn M, Kimmig R, Reiser MF.
Parametrial invasion in cervical carcinoma: evaluation of detection at MR
imaging with fat suppression.
Radiology (1998);206(1):125-9
196. Kimmig R, Hillemanns P, Hepp H.
Die diagnostische Hysteroskopie – ein neuer Standard.
Gynäkologe (1997);30:384-91
197. Kimmig R, Pfeiffer D, Landsmann H, Hepp H.
Quantitative determination of the epidermal growth factor receptor in cervical
cancer and normal cervical epithelium by 2-color flow cytometry: evidence for
down-regulation in cervical cancer.
Int J Cancer (1997); 22;74(4):365-73
198. Pfeiffer D, Spranger J, Al-Deiri M, Kimmig R, Fisseler-Eckhoff A, Scheidel P,
Schatz H, Jensen A, Pfeiffer A.
mRNA expression of ligands of the epidermal-growth-factor-receptor in the
uterus.
Int J Cancer (1997); 7;72(4):581-6
199. Hillemanns P, Kimmig R, Arnholdt H.
Conservative management of Sertoli-Leydig cell tumor of the ovary.
Acta Obstet Gynecol Scand (1997);76(6):604-7
200. Scheidler J, Heuck A, Wencke K, Kimmig R, Muller-Lisse U, Reiser M.
Parametrial infiltration of cervix carcinoma: diagnostic value of contrastenhanced
fat-suppressed T1-weighted SE sequences at 1.5 tesla.

Röfo (1997);166(4):312-6
201. Heuck A, Scheidler J, Kimmig R, Muller-Lisse U, Steinborn M, Helmberger T,
Reiser M.
Lymph node staging in cervix carcinomas: the results of high-resolution
magnetic resonance tomography (MRT) with a phased-array body coil.
Röfo (1997);166(3):210-4
202. Hillemanns P, Thaler C, Kimmig R.
Epidemiology and diagnosis of cervical intraepithelial neoplasia--is the
present concept of screening and diagnosis still current?
Gynäkol Geburtsh. Rundsch (1997);37(4):179-91
203. Scheidler J, Heuck AF, Bruening R, Kohz P, Kimmig R, Stehling MK, Reiser
MF.
Magnetic resonance imaging of the female pelvis. New circularly polarized
body array coil versus standard body coil.
Invest Radiol (1997);32(1):1-6
204. Kimmig R.
Diagnostik Gonadeninsuffizienz und Therapie Östogene in: Empfehlungen zu
Prävention, Diagnostik und Therapie der Osteoporose. (Hrsg: E. Senn, B.
Busch)
Manual der Arbeitsgruppe Osteoporose der Ludwig-Maximilians-Universität
München, 2. Auflage (1996)
205. Romisch M, Meier W, Kimmig R, Hepp H.
13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated,
recurrent squamous epithelial carcinoma of the cervix uteri and vulva.
Geburtshilfe Frauenheilkunde (1996);56(10):520-4
206. Regidor PA, Schindler AE, Buhler K, Gerhard I, Kimmig R, Meinen K,
Hoffmann G, Lubben G, Kienle E.
Results of long-term follow-up in treatment of endometriosis with the GnRH
agonist leuprorelin acetate depot (Enantone-Gyn monthly depot).
Zentralbl Gynäkol (1996);118(5):283-90
207. Gutschow K, Kimmig R.
Hormonsubstitution und gynäkologische Malignome, Krebsrisiko –
Lebensqualität.
Krebs (1995);14:49-54
208. Kimmig R.
Hysteroskopische Chirurgie.
Arch Gynecol Obstet (1995);257:21-9
209. Kimmig R.
Cabergolin – Ein neuer hypophysärer Dopamingonist.
Arzneimittelther (1995);13: 222-3
210. Kirschstein M, Untch M, Korell M, Hillemanns P, Kimmig R.
Durchflußzytometrische Untersuchungen zur Wirkungen von delta-
Aminolaevulinsäure (ALA) und Photodynamische Lasertherapie (PDT) auf
den Zellzyklus von Zervixkarzinomzellen.
Laser in der Medizin, Springer Heidelberg (1995), 254-8

211. Kimmig R, Knitza R (Hrsg.), Hepp F, Klocke G, Wagner C.
Gynäkologie pur, das Skript
Börm Bruckheimer Verlag GmbH, Grünwald (1995)
212. Kimmig R, Knitza R (Hrsg.), Hepp F, Klocke G, Wagner C.
Gynäkologie pur, die Karteikarten
Börm Bruckmeier Verlag GmbH, Grünwald (1995)
213. Kimmig R, Seehaus D, Scheidel P, Hepp H.
Hormonelle Substitution und orale Kontrazeption. Risiko der Induktion oder
Reaktivierung gynäkologischer Malignome.
Gynäkol Geburtsh. Rundsch (1995);35:72-8
214. Kimmig R, Landsmann H, Fileki M, Spelsberg H, Untch M, Kapsner T.
DNS-Zellzyklusanalyse beim Mammakarzinom nach Zytokeratinmarkierung
zur Identifizierung der Tumorzellen. Buchbeitrag in: Aktuelle Onkologie Band
86, Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie (Kreienberg
R, Grill HJ, Möbus V, Koldovsky U; Hrsg.).
Zuckschwerdt Verlag München Bern Wien New York (1995), S. 251-9
215. Kimmig R, Strowitzki T, Muller-Hocker J, Kurzl R, Korell M, Hepp H.
Conservative treatment of endometrial cancer permitting subsequent triplet
pregnancy.
Gynecol Oncol (1995);58(2):255-7
216. Gerber B, Krause A, Kimmig R.
Immunohistologic tumor cell detection in lymph nodes in node negative breast
cancer: correlation with "established" and "recent" prognostic factors.
Gynäkol Geburtsh. Rundsch (1995);35 Suppl 1:32-5
217. Kimmig R.
Hysteroscopic surgery.
Arch Gynecol Obstet (1995);257(1-4):21-9
218. Luppa P, Muller B, Jacob K, Kimmig R, Strowitzki T, Hoss C, Weber MM,
Engelhardt D, Lobo RA.
Variations of steroid hormone metabolites in serum and urine in polycystic
ovary syndrome after nafarelin stimulation: evidence for an altered corticoid
excretion.
J Clin Endocrinol Metab (1995);80(1):280-8
219. Kimmig R, Seehaus D, Scheidel P, Hepp H.
Hormonal replacement therapy and oral contraception. Risk of induction or
reactivation of gynecologic malignancies.
Gynäkol Geburtshilfliche Rundsch (1995);35(2):72-8
220. Kimmig R, Kürzl R, Höß C, Landsmann H.
(Redaktion) für die Projektgruppe Zervix- und Endometriumkarzinom des
Tumorzentrums München. Manual: Zervixkarzinom: Empfehlungen zur
Diagnostik, Therapie und Nachsorge, Tumorzentrum München (1994)
221. Kimmig R, Klocke G und Hepp H.
Erfordernisse der präoperativen Diagnostik bei gynäkologischen

Erkrankungen im kleinen Becken.
Radiologie (1994);34:346-50
222. Kimmig R, Kapsner T, Spelsberg H, Untch M, Hepp H.
DNA cell-cycle analysis of cervical cancer by flow cytometry using
simultaneous cytokeratin labeling for identification of tumor cells.
J Cancer Res Clin Oncol (1995);121(2):107-14
223. Kimmig R, Seehaus D, Scheidel P, Hepp H.
Krebserkrankungen – hormonelle Substitution – orale Kontrazeption.
Kongresszeitung 50. Kongreß der Deutschen Gesellschaft für Gynäkologie
und Geburtshilfe (1994) S. 12-14
224. Kimmig R, Egner D, Hepp H.
Durchflußzytometrische DNS-Analyse maligner epithelialer gynäkologischer
Tumoren. In: Tumorimmunologie in der Gynkökologie (Koldovsky U,
Kreienberg R, Hrsg.)
Zuckschwerdt Verlag München Bern Wien New York (1994) S. 124-31
225. Kürzl R, Kimmig R, Schürmann H.
(Redaktion) für die Projektgruppe Zervix- und Endometriumkarzinom des
Tumorzentrums München. Manual: Endometriumkarzinom. Empfehlung zur
Diagnostik, Therapie und Nachsorge, Tumorzentrum München (1994).
226. Webster J, Piscitelli G, Polli A, Ferari Cl, Ismail I.
Scanlon MF fort he Cabergonline Comparative Study Group*,*…R. Kimmig
and O.A. Muller, Munich, Germany; …. Cabergoline versus bromodcriptine in
the treatment of hyperprolactinemic amenorrhea.
New Engl J Med (1994);331:904-09
227. Schindler AE, Bühler K, Gerhard I, Wiedemann R, Kimmig R, Schüssler B,
Kranzfelder D, Mall-Häfeli M, Meinen K, Mancarella D, Hofmann G.
Behandlung der Endometriose mit dem GnRH-Agonisten Leuprorelinacetat
Depot (Enantone Gyn Monats-Depot): Eine multizentrische Studie.
Zentralbl Gynäkol (1994);116:679-86
228. Kimmig R, Spelsberg H, Kapsner T, Untch M, Hepp H.
Flow cytometric DNA analysis of breast cancer by two colour method using
cytokeratin labeling for identification of tumour cells.
Anal Cell Pathol (1994);7(3):205-15
229. Kimmig R, Klocke G, Hepp H.
Requirements in preoperative diagnosis of gynecologic diseases of the pelvis
Radiologe (1994);34(7):346-50
230. Schindler AE, Buhler K, Gerhard I, Wiedemann R, Kimmig R, Schussler B,
Kranzfelder D, Mall-Hafeli M, Meinen K, Mancarella D, et al.
Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot
(Enatone-Gyn monthly depot): a multicenter study.
Zentralbl Gynäkol (1994);116(12):679-86
231. Kimmig R, Ratzel R.
Eigenblutspende in Gynäkologie und Geburtshilfe. Stellungnahme der
Deutschen Gesellschaft für Gynäkologie und Geburtshilfe.
Der Frauenarzt (1993);34:606-7

232. Kimmig R.
Metergolin – ein hypophysärer Dopaminagonist.
Arzneimittelther (1993);11:143-4
233. Kimmig R.
Nafarelin – GnRH-Agonist zur Behandlung der Endometriose.
Arzneimittelther (1993);11:145-7
234. Kimmig R, Pfeiffer D, Pfeiffer A, Hepp H.
Bestimmung des EGF-Rezeptors zur Prognoseeinschätzung des
Zervixkarzinoms.
Arch Gynecol Obstet (1993);254:1028-30
235. Kimmig R, Hasbargen U, Hepp H.
Hysteroscopic staging of endometrial cancer. Comment on the contribution by
R. Schild, Th. Kutter
Geburtshilfe und Frauenheilkunde (1993);53(6):433-4
236. Untch M, Nestle-Kramling C, Konecny G, Harbeck N, Funke I, Kimmig R,
Hepp H.
Prognostic value of tumor cells in bone marrow in breast cancer.
Gynäkol Geburtsh. Rundsch (1993);33 Suppl 1:308-10
237. Kimmig R, Untch M, Pfeiffer D, Egner D, Strowitzki T, Hepp H.
Multiparametric flow cytometry determination of the EGF receptor and DNA
cell cycle distribution in cervix cancer.
Gynäkol Geburtsh. Rundsch (1993);33 Suppl 1:283-4
238. Gerhard I, Schindler AE, Buhler K, Winkler U, Meinen K, Mancarella D,
Hoffmann G, Schussler B, Kimmig R, Kranzfelder D.
Treatment of endometriosis with leuprorelin acetate depot: a German
multicentre study.
Clin Ther (1992);14 Suppl A:3-16
239. Kimmig R, Hasbargen U, Hepp H.
Hysteroskopisches Staging des Endometriumkarzinoms.
(zum Beitag: R. Schild, Th. Kutter. Geburtsh. und Frauenheilk. 52 (1992) 467-
470).
Geburtshilfe und Frauenheilkunde:(1993);53 433-434
240. Kimmig R.
Standardlagerungen: Buchbeitrag in: Hepp H, Scheidel P, Schüßler B,
Gynäkologische Standardoperationen.
Ferdinand Enke, Stuttgart (1991):373-8
241. Gerhard I, Schindler AR, Bühler K, Winkler U, Meinen K, Mancella D,
Hoffmann G, Schüssler B, Kimmig R, Kranzfelder D.
Treatment of endometriosis with leuprorelin acetate depot: a German
multicentre study.
Clin Ther (1991);14 Suppl A:3-16
242. Strowitzki T, Wiedemann R, Kimmig R, Hepp H.
Einfluß von EGF, IGF-1 und Wachstumshormon auf endometriale

Stromazellen in vitro.
Arch Gynecol Obstet 250: (1991) 1015-1016
243. Kimmig R, Egner D, Spelsberg H, Untch M, Kapsner Th.
Durchflußzytometrische DNA-Analyse bei Mammakerzinomen: Korrelaton mit
klinischen Prognosefaktoren.
Arch Gynecol Obstet (1991);250: 209-210
244. Luppa P, Neumeier D, Kimmig R.
Rationelle Labordiagnostik des Hyperandrogenismus der Frau.
Ärztl Lab (1989);35:247-52
245. Pfeiffer DG, Ritz P, Kimmig R, Mann K, Scheidel P.
EGF and TGF-beta: effects on growth and on the secretion of beta-HCG in
cervical carcinoma cells.
Acta Endo (1989);120 (S):145-146
246. Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldovsky U,
Schneweis KE, Seedorf K, Gissmann L.
Antibodies against the human papillomavirus type 16 early proteins in human
sera: correlation of anti-E7 reactivity with cervical cancer.
J Natl Cancer Inst (1989);81(22):1698-1704
247. Hartl WH, Jauch KW, Kimmig R, Wicklmayr M, Gunther B, Heberer G.
Minor role of ketone bodies in energy metabolism by skeletal muscle tissue
during the postoperative course.
Ann Surg (1988);207(1):95-101
248. Kimmig R.
Über die Kurzzeitregulation des Leberstoffwechsels durch Glucagon:
Wirkungen auf Glykogenolyse, Glykolyse, Sauerstoffverbrauch und
Ketogenese, Kinetiken der direkten und indirekten Glucagoneffekte,
Interaktionen der Stoffwechsel-prozesse im “transient” und im “steady state”,
untersucht in der isolierten, nichtrezirkulierend perfundierten Rattenleber.
Inauguraldissertation an der Ludwig-Maximillians-Universität München. (1986)
249. Kimmig R, Mauch TJ, Scholz R.
Actions of glucagon on flux rates in perfused rat liver. 2. Relationship between
inhibition of glycolysis and stimulation of respiration by glucagon.
Eur J Biochem (1983) 15;136(3):617-20
250. Kimmig R, Mauch TJ, Kerzl W, Schwabe U, Scholz R.
Actions of glucagon on flux rates in perfused rat liver. 1. Kinetics of the
inhibitory effect on glycolysis and the stimulatory effect on glycogenolysis.
Eur J Biochem (1983) 15;136(3):609-16